New hope for kids with rare bone disease: experimental drug enters final testing
NCT ID NCT06079359
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ALXN1850 in children aged 2 to 12 with hypophosphatasia, a rare genetic condition that weakens bones. The trial compares the drug to a placebo to see if it improves bone health and movement. About 30 children who have not received prior treatment for this condition will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALXN1850
What this could lead to
If it works, this could provide a new treatment option for children with hypophosphatasia, improving bone strength and physical function.
What could go wrong
This is an early-stage Phase 3 trial with only 30 participants, so results may not apply to all patients. The drug may not work better than placebo or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Baltimore, Maryland, 21287, United States
-
Research Site
Kansas City, Missouri, 64108, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Parkville, 3052, Australia
-
Research Site
Brussels, 1020, Belgium
-
Research Site
Brasília, 71625-009, Brazil
-
Research Site
Porto Alegre, 90610-261, Brazil
-
Research Site
Recife, 50740-465, Brazil
-
Research Site
Salvador, 40050-410, Brazil
-
Research Site
São Paulo, 01409-902, Brazil
-
Research Site
São Paulo, 05403-900, Brazil
-
Research Site
Calgary, Alberta, T2E 7H7, Canada
-
Research Site
Winnepeg, Manitoba, R3E 3P4, Canada
-
Research Site
Beijing, 100045, China
-
Research Site
Guangzhou, 510623, China
-
Research Site
Shanghai, 2000127, China
-
Research Site
Shenzhen, 518053, China
-
Research Site
Helsinki, 00290, Finland
-
Research Site
Ashkelon, 7830604, Israel
-
Research Site
Chihuahua City, 31238, Mexico
-
Research Site
Lodz, 93-338, Poland
-
Research Site
Bucharest, 011863, Romania
-
Research Site
Madrid, 28046, Spain
-
Research Site
Vitoria-Gasteiz, 01009, Spain
-
Research Site
Stockholm, 17176, Sweden
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Ankara, 06560, Turkey (Türkiye)
-
Research Site
Bursa, 16059, Turkey (Türkiye)
-
Research Site
Erzurum, 25240, Turkey (Türkiye)
-
Research Site
Istanbul, 34899, Turkey (Türkiye)
-
Research Site
Birmingham, B4 6NH, United Kingdom